Nektar Therapeutics

Serina Therapeutics, Inc.

Nektar Therapeutics Al, Corporation

Shearwater Corporation

Applied Research Systems Ars Holding N.v.

Other

United Therapeutics Corporation

Shearwater Polymers, Inc.

Sarina Therapeutics, Inc.

Michael David Bentley

Xuan Zhao

J Milton Harris

Xiaoming Shen

Zhihao Fang

Tacey Viegas

Kunsang Yoon

Antoni Kozlowski

Samuel P McManus

Mary J Bossard

Randall Moreadith

Ping Zhang

Sean M Culbertson

Zhongxu Ren

Rebecca Weimer

Stephen A Charles

Lihong Guo

Bekir Dizman

William Dudley Battle, Iii

Michael James Roberts

Tacey X Viegas

Jennifer A Riggs-Sauthier

Tony L Sander

Richard R Goodin

Lin Cheng

Francesco Maria Veronese

Nabil El-Tayar

Wen Zhang

Michael Reif

Samuel P Mcmanus

Robert G Shorr

Guerin D Rife

David B Leadbetter

Martine A Rothblatt

Harold Zappe

Anna Mero

Robert J Sharpe

Kevin Burton

Xuan Zhoa

Jeremy Lloyd Clark

Rainer Jordan

Rainer Jordon

William Dudley Battle

Ribecca Weimer

Xioaming Shen

POZ-lipid conjugates and lipid nanoparticles (LNPs) including POZ-lipid conjugates used to facilitate delivery of an encapsulated payload. LNPs including POZ-lipid conjugates and a nucleic acid payload such as, but not limited to, mRNA or modified mRNA are disclosed. Such LNPs have no immunogenicity or reduced immunogenicity as compared to a corresponding LNP containing a PEG-lipid.

Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including same

Methods of preparing monodisperse oligomer reagent compositions such as oligo(ethylene glycol) reagent compositions are described herein. The methods involve reacting a halo-terminated oligomer such as an oligo(ethylene oxide) having (m) monomers with a hydroxyl-terminated oligomer such as a hydroxyl-terminated oligo(ethylene oxide) having (n) monomers.

Methods of preparing a monodisperse oligo(ethylene glycol) reagent composition

The present disclosure provides polymer conjugates comprising a polymer and an agent the agent linked to the polymer via a linking group containing a cleavable moiety.

Subcutaneous delivery of polymer conjugates of therapeutic agents

The present disclosure provides copolymers of 2-substituted-2-oxazolines possessing two or three reactive functional groups which are also chemically orthogonal. The copolymers described may be random copolymers, block copolymers or a mixture of random and block copolymer configurations. Furthermore, the present disclosure provides novel methods for synthesizing the above polymers and for conjugating to molecules such as targeting, diagnostic and therapeutic agents.

Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same

Described are conjugates comprising a water-soluble polymer linked to a compound comprising a catechol moiety via a cleavable linkage, wherein the cleavable linkage is formed between the water-soluble polymer and a first phenolic hydroxyl group of the catechol moiety and a second phenolic hydroxyl group of the catechol moiety is linked to a blocking group wherein the rate of hydrolytic release of the compound comprising the catechol moiety is controlled, at least in part, through structure or design of the blocking group on the second phenolic hydroxyl group of the catechol moiety. Therefore, the rate of hydrolytic release of the compound comprising the catechol moiety can be tuned through structural design of the group on the second phenolic hydroxyl group of the catechol moiety. Compounds used in the synthesis of the described conjugates and methods of using the described conjugate and other compounds in the treatment of dopamine-responsive disorders are also described.

Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the same

The invention provides corticosteroids that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits a reduced biological membrane crossing rate as compared to the biological membrane crossing rate of the corticosteroid not attached to the water-soluble oligomer.

Oligomer-corticosteroid conjugates

Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.

Polymer derivatives having particular atom arrangements

The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a cleavable moiety.

Subcutaneous delivery of polymer conjugates of therapeutics agents

The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. The conjugates as well as the polymeric reagents used to form the conjugates include at least one of each the following: an aromatic moiety comprising an ionizable hydrogen atom, a spacer moiety, and a water-soluble polymer. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided.

Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates

The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.

Subcutaneous delivery of poly(oxazoline) polymer conjugates

Conjugates of a Factor VIII moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising the conjugates, methods of making the conjugates, and methods of administering compositions comprising the conjugates to a patient.

Method of making a water-soluble polymer-factor VIII moiety conjugate

In the present disclosure, polymer conjugates, including polymer-antibody-drug conjugates (polymer ADCs) are described, as well as the use of such conjugates to treat human disease. The polymer conjugates can contain a large number of polymer-bound agents, thus effectively increasing the drug antibody ration (DAR) of the antibody significantly beyond the currently available technology. This may be of particular importance when antibodies to low density antigens are used as target antibodies. The described polymer-ADCs have improved pharmacokinetics and solubility relative to traditional ADCs. The linker between agent and the polymer can be tailored to provide release of toxin at the desired site and under the desired conditions within the tumor. An additional feature of the polymer-ADCs of the current disclosure is that a purification moiety can be attached to the polymer backbone to provide ease of purification of the polymer-ADCs.

Polyoxazoline antibody drug conjugates

The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.

Activated polyoxazolines and conjugates and compositions comprising the same

Composition comprising a polymeric reagent

Growing community of inventors

Huntsville, AL, United States of America

Michael David Bentley